No special patient preparation is necessary
Tube Type:
One 2.7 mL 3.2% sodium citrate (light-blue top) tube
Alternative: 1.8 mL 3.2% sodium citrate tube (available for pediatric patients or difficult draws)
Also acceptable: Two 0.5 mL aliquots, frozen, platelet poor citrated plasma minimum
Aliquot tubes must be polypropylene
Collection Details:
Venipuncture using a 19- to 21-gauge needle is recommended to minimize hemolysis. If multiple specimens are collected, adhere to policy for order of draw
Tubes MUST be full. DO NOT overfill or underfill
Tube MUST be mixed immediately after filling with blood
Gently mix tube by inverting 5 to 6 times. Vigorous mixing or shaking may cause hemolysis, which will affect the result
DO NOT draw blood into a heparinized syringe or from a heparinized line
If unavoidable:
Flush the line with 5 mL saline, AND
Discard at least the first 5 mL of blood or six dead-space volumes of the vascular access device
For patients with hematocrit >55%, the citrate concentration should be adjusted. A special draw tube is available upon request - call Core Lab 402-559-9113.
Transport room temp
Centrifuge and test within 4 hours.
If testing cannot be completed within 4 hours, prepare platelet poor plasma and freeze at -20 C.
To prepare platelet poor plasma:
Centrifuge at ~3700 x g for 10 minutes at room temperature, or other current validated setting for producing platelet poor plasma
Using a plastic disposable pipette, carefully transfer the top ¾ of the plasma into a polypropylene tube, avoiding the buffy coat. DO NOT pour off.
If necessary, repeat centrifugation. Transfer the top ¾ of the plasma from the second spin into a polypropylene tube, again avoiding the buffy coat.
The residual platelet count MUST be < 10,000/uL. Each laboratory must validate its centrifugation method to consistently produce platelet poor plasma.
Inspect the plasma for clots or visible hemolysis.
Cap and freeze at -20 C immediately
Coagulation
Daily, Routine or STAT
402-559-9113
Clinical applications for this test are as follows: Disseminated Intravascular Coagulation (DIC), negative predictor for the diagnosis of a thrombotic episode (i.e. DVT,PE), efficacy of treatment for a thrombotic episode and screen for possible reoccurrence (MI), and screen for other activation states of coagulation (i.e. postoperative, cancer , cirrhosis).
Description: The specific degratation of fibrin (i.e. fibrinolysis) is the reactive mechanism responding to the formation of fibrin. Plasmin is the fibrinolytic enzyme derived from inactive plasminogen. Plasminogen is converted into plasmin by plasminogen activators. The main plasmingen activators are tissue plasminogen activator (tPA) and pro-urokinase which is activated into urokinase (UK) by, among others, the contact system of coagulation. In the blood stream, plasmin is rapidly and specifically neutralized by alpha 2-antiplasmin, thereby restricting its fibrinogenolyic activity and localizes the fibrinolysis on the fibrin clot. On the fibrin clot plasmin degrades fibrin into various products, (i.e. D-Dimers). Antibodies specific for these products, which do not recognize fibrinogen, have been developed. The presence of these various fibrin degradation products (FDPs), among which D-Dimer is the terminal product, is the proof that the fibrinolytic system is in action in response to coagulation activation.
Coagulation
Daily, Routine or STAT
402-559-9113
Main Lab: Instrumentation Laboratory ACL Top 750
Oakview: Instrumentation Laboratory ACL Top 300
Bellevue: Instrumentation Laboratory ACL Top 350
Results same day.
STAT results within 1 hour.
Routine results within 2 hours
Main Lab, Oakview Lab, and Bellevue lab: Normal = <500 ng/ml FEU
Grand Island lab only: Normal = <230 ng/ml D-DU
(FEU = Fibrinogen Equivalent Units)
| 85379 |
| OrderCode | OrderName | ResultCode | ResultName | ResultUnits | LOINC | CPT |
| DIMER | D-DIMER | DIMER | D-DIMER | ng/mL FEU | 48065-7 | 85379 |
| Collection |
No special patient preparation is necessary
Tube Type:
One 2.7 mL 3.2% sodium citrate (light-blue top) tube
Alternative: 1.8 mL 3.2% sodium citrate tube (available for pediatric patients or difficult draws)
Also acceptable: Two 0.5 mL aliquots, frozen, platelet poor citrated plasma minimum
Aliquot tubes must be polypropylene
Collection Details:
Venipuncture using a 19- to 21-gauge needle is recommended to minimize hemolysis. If multiple specimens are collected, adhere to policy for order of draw
Tubes MUST be full. DO NOT overfill or underfill
Tube MUST be mixed immediately after filling with blood
Gently mix tube by inverting 5 to 6 times. Vigorous mixing or shaking may cause hemolysis, which will affect the result
DO NOT draw blood into a heparinized syringe or from a heparinized line
If unavoidable:
Flush the line with 5 mL saline, AND
Discard at least the first 5 mL of blood or six dead-space volumes of the vascular access device
For patients with hematocrit >55%, the citrate concentration should be adjusted. A special draw tube is available upon request - call Core Lab 402-559-9113.
Transport room temp
Centrifuge and test within 4 hours.
If testing cannot be completed within 4 hours, prepare platelet poor plasma and freeze at -20 C.
To prepare platelet poor plasma:
Centrifuge at ~3700 x g for 10 minutes at room temperature, or other current validated setting for producing platelet poor plasma
Using a plastic disposable pipette, carefully transfer the top ¾ of the plasma into a polypropylene tube, avoiding the buffy coat. DO NOT pour off.
If necessary, repeat centrifugation. Transfer the top ¾ of the plasma from the second spin into a polypropylene tube, again avoiding the buffy coat.
The residual platelet count MUST be < 10,000/uL. Each laboratory must validate its centrifugation method to consistently produce platelet poor plasma.
Inspect the plasma for clots or visible hemolysis.
Cap and freeze at -20 C immediately
Coagulation
Daily, Routine or STAT
402-559-9113
Clinical applications for this test are as follows: Disseminated Intravascular Coagulation (DIC), negative predictor for the diagnosis of a thrombotic episode (i.e. DVT,PE), efficacy of treatment for a thrombotic episode and screen for possible reoccurrence (MI), and screen for other activation states of coagulation (i.e. postoperative, cancer , cirrhosis).
Description: The specific degratation of fibrin (i.e. fibrinolysis) is the reactive mechanism responding to the formation of fibrin. Plasmin is the fibrinolytic enzyme derived from inactive plasminogen. Plasminogen is converted into plasmin by plasminogen activators. The main plasmingen activators are tissue plasminogen activator (tPA) and pro-urokinase which is activated into urokinase (UK) by, among others, the contact system of coagulation. In the blood stream, plasmin is rapidly and specifically neutralized by alpha 2-antiplasmin, thereby restricting its fibrinogenolyic activity and localizes the fibrinolysis on the fibrin clot. On the fibrin clot plasmin degrades fibrin into various products, (i.e. D-Dimers). Antibodies specific for these products, which do not recognize fibrinogen, have been developed. The presence of these various fibrin degradation products (FDPs), among which D-Dimer is the terminal product, is the proof that the fibrinolytic system is in action in response to coagulation activation.
| Ordering |
Coagulation
Daily, Routine or STAT
402-559-9113
Main Lab: Instrumentation Laboratory ACL Top 750
Oakview: Instrumentation Laboratory ACL Top 300
Bellevue: Instrumentation Laboratory ACL Top 350
Results same day.
STAT results within 1 hour.
Routine results within 2 hours
| Result Interpretation |
Main Lab, Oakview Lab, and Bellevue lab: Normal = <500 ng/ml FEU
Grand Island lab only: Normal = <230 ng/ml D-DU
(FEU = Fibrinogen Equivalent Units)
| Administrative |
| 85379 |
| RPS Interface Information |
| OrderCode | OrderName | ResultCode | ResultName | ResultUnits | LOINC | CPT |
| DIMER | D-DIMER | DIMER | D-DIMER | ng/mL FEU | 48065-7 | 85379 |
